Positioning Therapy for Crohn’s Disease

Inflammatory Bowel Disease (S Hanauer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease


The therapy of Crohn’s disease is constantly evolving. It is widely recognized that clinical assessment does not stage disease activity accurately and that endoscopic healing is associated with improved long-term outcomes. Disease management is therefore transitioning to a new paradigm that includes direct assessment of disease severity (endoscopically in most patients), followed by assessment of mucosal healing. New approaches have helped optimize the use of the thiopurines, methotrexate and anti-TNF agents. Novel agents with different mechanisms of action are expanding our therapeutic armamentarium. The major challenge of the future will be to identify patient subgroups best suited to particular therapeutic approaches. In the meantime, studies of comparative effectiveness will be crucial in positioning therapies relative to each other.


Crohn’s disease Immunomodulators Anti-TNF Antibodies 



6-methyl-mercaptopurine ribonucleotides


6-thioguanine nucleotides






Azathioprine for Treatment of Early Crohn’s disease in adults


Crohn’s disease


Crohn’s disease activity index


Confidence interval


Combination of Maintenance Methotrexate-Infliximab Trial


Certolizumab pegol


Epstein-Barr Virus


Hazard ratio












Odds ratio


Résultat de l’Adjonction Précoce d’ImmunoDépresseurs


Red blood cells


Relative Risk


Standardized incidence ratio


Tumor necrosis factorα


Thiopurine methyltransferase


Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. 1.
    Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62(12):1806–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Camus M, Seksik P, Bourrier A, et al. Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(4):389–94.Google Scholar
  3. 3.
    Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107(4):579–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59(9):1200–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn’s disease. Am J Gastroenterol. 2009;104(11):2754–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60(7):930–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74. e761.PubMedCrossRefGoogle Scholar
  8. 8.
    Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65. e752; quiz e714-755.PubMedCrossRefGoogle Scholar
  9. 9.•
    Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn’s disease. Aliment Pharmacol Ther. 2014;39(2):163–75. Azathioprine doses as high as 3.5 mg/kg/day are not sufficient to raise 6-TGN concentrations into the therapeutic range. PubMedCrossRefGoogle Scholar
  10. 10.
    Angelberger S, Schaeffeler E, Teml A, et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn’s disease and azathioprine metabolite levels. Inflamm Bowel Dis. 2013;19(3):590–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122(4):904–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohn’s Colitis. 2009;3(3):162–7.CrossRefGoogle Scholar
  13. 13.
    Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(2):209–14.Google Scholar
  14. 14.
    Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohn’s Colitis. 2012;6(9):905–12.CrossRefGoogle Scholar
  15. 15.
    Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86(4):539–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New Engl J Med. 2010;362(15):1383–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59(10):1363–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–31.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(7):826–31.Google Scholar
  20. 20.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. New Engl J Med. 2003;348(7):601–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mantzaris GJ, Viazis N, Petraki K, et al. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol. 2009;21(9):1042–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33. quiz 591.PubMedCrossRefGoogle Scholar
  23. 23.
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38.PubMedCrossRefGoogle Scholar
  25. 25.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137(5):1628–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S. Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36(11–12):1040–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohn’s Colitis. 2013;7(2):154–60.CrossRefGoogle Scholar
  29. 29.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. New Engl J Med. 2007;357(3):228–38.PubMedCrossRefGoogle Scholar
  30. 30.
    Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(8):670–8. e673.Google Scholar
  31. 31.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. New Engl J Med. 2007;357(3):239–50.PubMedCrossRefGoogle Scholar
  32. 32.•
    Beaugerie L. Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology. 2013;145(5):927–30. An excellent review of thiopurine-associated lymphoma. PubMedCrossRefGoogle Scholar
  33. 33.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Khan N, Abbas AM, Lichtenstein GR, Loftus Jr EV, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15. e1003.PubMedCrossRefGoogle Scholar
  36. 36.
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118(6):1018–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn’s disease in a decision analytic model. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(1):46–51.Google Scholar
  38. 38.••
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22. The final safety data of a large infliximab registry. PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.••
    Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–8. Prednisone induction and hydrocortisone premedication are effective in preventing the formation of antibodies to infliximab and in enhancing response. PubMedCrossRefGoogle Scholar
  40. 40.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124(4):917–24.PubMedCrossRefGoogle Scholar
  41. 41.
    Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther. 2012;35(12):1397–407.PubMedCrossRefGoogle Scholar
  42. 42.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedCrossRefGoogle Scholar
  43. 43.•
    Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut. 2013;62(2):201–8. Certolizumab induces endoscopic healing. PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.•
    Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–11. Adalimumab induces endoscopic healing. PubMedCrossRefGoogle Scholar
  45. 45.
    Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn’s disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20(8):838–48.PubMedCrossRefGoogle Scholar
  46. 46.
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.PubMedCrossRefGoogle Scholar
  47. 47.
    Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol. 2005;17(10):1047–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135(5):1493–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(10):1248–54.Google Scholar
  52. 52.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol. 2011;46(3):310–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Van Moerkercke W, Ackaert C, Compernolle G, et al. High infliximab trough levels are associated with mucosal healing in Crohn’s disease. Gastroenterology. 2010;138(5 (Supplement 1)):S-60.Google Scholar
  54. 54.
    Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26(11–12):1509–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn’s disease. Inflamm Bowel Dis. 2013;19(6):1112–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12(3):423–31. e421.Google Scholar
  57. 57.
    Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(10):1079–87. quiz e1085-1076.Google Scholar
  58. 58.
    West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28(9):1122–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60(1):41–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Afif W, Loftus Jr EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9.PubMedCrossRefGoogle Scholar
  61. 61.•
    Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71. Infliximab therapy may be continued in patients with low titer, transient antibodies to infliximab. PubMedCrossRefGoogle Scholar
  62. 62.
    Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(4):444–7.Google Scholar
  63. 63.
    Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8(7):591–9. e591; quiz e578-599.Google Scholar
  64. 64.••
    Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70. e65; quiz e31. Inflimimab therapy may be stopped in 55 % of patients on combination therapy with an immunomodulator. PubMedCrossRefGoogle Scholar
  65. 65.
    Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–23.PubMedCrossRefGoogle Scholar
  66. 66.
    Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–50. e441; quiz 716.PubMedCrossRefGoogle Scholar
  67. 67.
    Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J Crohn’s Colitis. 2012;6(9):924–31.CrossRefGoogle Scholar
  68. 68.
    Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab–a pilot study. Dig Dis Sci. 2012;57(5):1341–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106(12):2146–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–63.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF-alpha Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology. 2013;145(6):1464–78.PubMedCrossRefGoogle Scholar
  72. 72.
    Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59.PubMedCrossRefGoogle Scholar
  73. 73.
    Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268–76.PubMedCrossRefGoogle Scholar
  74. 74.
    Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):30–5.Google Scholar
  75. 75.
    Norgard BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with Crohn’s disease–a nationwide cohort study. Aliment Pharmacol Ther. 2013;37(2):214–24.PubMedCrossRefGoogle Scholar
  76. 76.
    Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohn’s Colitis. 2013;7(11):853–67.CrossRefGoogle Scholar
  77. 77.•
    Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. New Engl J Med. 2013;369(8):711–21. Pivotal trial of vedolizumab. PubMedCrossRefGoogle Scholar
  78. 78.•
    Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. New Engl J Med. 2012;367(16):1519–28. Pivotal trial of ustekinumab. PubMedCrossRefGoogle Scholar
  79. 79.
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130(4):1047–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Alexandra Gutierrez
    • 1
    • 2
  • Themistocles Dassopoulos
    • 1
    • 2
  1. 1.Section of Gastroenterology and Hepatology, Department of MedicineWashington University in St. LouisSt. LouisUSA
  2. 2.Gastroenterology DivisionWashington University School of MedicineSt. LouisUSA

Personalised recommendations